September 8, 2022

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention: Jordan Nimitz



Tango Therapeutics, Inc.

Acceleration Request for Registration Statement on Form S-3

File No. 333-267224

Dear Ms. Nimitz,

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Tango Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to September 12, 2022, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling William Collins at (617) 570-1447.

If you have any questions regarding this request, please contact William Collins of Goodwin Procter LLP at (617) 570-1447.



/s/ Barbara Weber

Barbara Weber
Chief Executive Officer and President

Daniella Beckman, Tango Therapeutics, Inc.

Douglas Barry, Tango Therapeutics, Inc.

William Collins, Esq., Goodwin Procter LLP